Genzyme 4Q Revenue: $854.2 million (+17%) 4Q Earnings: $209 million (+29%) FY Revenue: $3.2 billion (+17%) FY Loss: $16.8 million (earnings were $441.5 million FY2005) Comments: Myozyme for Pompe disease was launched in Europe and the U.S. in 2Q2006, and sales for the year were $59 million. Fabrazyme sales were $359 million and Cerezyme sales were $1 billion for the year. Sales of Renagel were $515 million and sales of Synvisc were $234 million for the year. FY Loss includes a charge o...